FLGT (Fulgent Genetics) Stock Based Compensation: $38.9 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FLGT Fulgent Genetics Inc FLGT
64 GF Score
Price $20.55
GF Value $24.15
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Fulgent Genetics Stock Based Compensation?

Fulgent Genetics FLGT -2.19% 64 Stock Based Compensation is $38.9 Mil as of Mar. 2026. GuruFocus rates FLGT with a GF Score™ of 64/100 and a GF Value™ of $24.15 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Fulgent Genetics's Stock Based Compensation for the three months ended in Mar. 2026 was $9.9 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $38.9 Mil.

Fulgent Genetics Stock Based Compensation Related Terms

Fulgent Genetics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Fulgent Genetics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fulgent Genetics Stock Based Compensation Chart

Fulgent Genetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.88 32.64 42.92 44.48 39.58

Fulgent Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.55 10.04 9.72 9.28 9.89
FLGT
64GF Score
Fulgent Genetics Inc FLGT
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fulgent Genetics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $38.9 Mil.

What does a Stock Based Compensation of $38.9 Mil mean?
Fulgent Genetics (FLGT) has a Stock Based Compensation of $38.9 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Fulgent Genetics and its competitors.
Is Fulgent Genetics' Stock Based Compensation too high?
Fulgent Genetics' current Stock Based Compensation is $38.9 Mil. Overall, Fulgent Genetics has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' Stock Based Compensation compare to MYGN and CSTL?
Fulgent Genetics' Stock Based Compensation of $38.9 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Diagnostics & Research company?
A good Stock Based Compensation depends on the Medical Diagnostics & Research industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Fulgent Genetics and its competitors. Fulgent Genetics's current Stock Based Compensation is $38.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (FLGT) is currently considered Modestly Undervalued. The stock's GF Value™ is $24.15, compared to a current price of $20.55 — trading 14.9% below its estimated fair value. The current Stock Based Compensation is $38.9 Mil. Fulgent Genetics' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Fulgent Genetics (FLGT), the current Stock Based Compensation is $38.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fulgent Genetics (FLGT) Overvalued in 2026?

Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued. The current stock price of $20.55 is trading 14.9% below its estimated GF Value™ of $24.15. GuruFocus considers Fulgent Genetics to be Modestly Undervalued.

Key valuation signals for FLGT:

  • Stock Based Compensation: $38.9 Mil
  • GF Value™: $24.15 vs. price of $20.55 (14.9% below fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the FLGT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fulgent Genetics Business Description

Other Exchanges FLGT:Mexico
Address 4399 Santa Anita Avenue, El Monte, CA, USA, 91731
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
64GF Score

Get the complete analysis for FLGT

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.55
Price
$24.15
GF Value